-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

641.O2.6 641. CLL: Biology and Pathophysiology, excluding Therapy: Mechanisms of Action and Resistance to Targeted Agents

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Diseases, Leukemia, CLL, Biological Processes, Lymphoid Malignancies, signal transduction
Monday, December 3, 2018: 7:00 AM-8:30 AM
Grand Ballroom 5 (Marriott Marquis San Diego Marina)
Versha Banerji, MD, University of Manitoba and Michael E. Williams, MD, UVA Health System Hospital West
Banerji: Roche: Consultancy, Honoraria, Other: Unrestricted grant received in the past; Gilead: Consultancy, Honoraria, Other: Unrestricted grant received in the past; Astra- Zeneca: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Other: Unrestricted grant received in the past; Abbvie: Consultancy, Honoraria, Other: Unrestricted grant received in the past; Teva: Consultancy, Honoraria, Other: Unrestricted grant received in the past. Williams: Janssen: Consultancy, Honoraria, Research Funding; Pharmacyclics: Research Funding; Celgene: Consultancy, Research Funding; Abbvie: Consultancy; Astra-Zeneca: Consultancy; Gilead: Consultancy, Research Funding; Novartis: Research Funding; Takeda: Research Funding; Kite: Consultancy; Juno: Consultancy; TG Therapeutics: Consultancy; Verastem: Consultancy; Seattle Genetics: Consultancy; Sandoz: Consultancy.
7:00 AM

Laura Beckmann, MD1*, Valeska Berg, Ph.D.1*, Clarissa Dickhut2*, Johannes Bloehdorn, MD3*, Jasmin Bahlo, PhD4*, Sandra Robrecht, PhD5*, Malte Hülsemann, MD1*, Stefan Loroch2*, Olaf Merkel1*, Kirsten Fischer, MD4*, Clemens-Martin Wendtner, MD6, Stephan Stilgenbauer, MD7,8,9, Albert Sickmann, PhD2*, Michael Hallek, MD5,10*, René Zahedi, PhD11* and Lukas P. Frenzel, MD1,12*

1University of Cologne, Department of Internal Medicine I, Center of Integrated Oncology Cologne-Bonn, Germany, Cologne, Germany
2Leibniz Institute - ISAS, Dortmund, Germany
3Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
4Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital Cologne, Cologne, Germany
5Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital, Cologne, Germany
6Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany
7Department of Hematology, Oncology, Rheumatology and Clinical Immunology, Saarland University Medical Center, Homburg, Germany
8Department III of Internal Medicine, Ulm University, Ulm, Germany
9Klinik für Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg, Germany
10University Hospital of Cologne, Cologne, Germany
11Jewish General Hospital - Lady Davis Proteomics Centre, Montreal, Canada
12Cologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany

7:15 AM

Anne Quinquenel1*, Luc Mathieu Fornecker2*, Remi Letestu3*, Carole Fleury4*, Loic Ysebaert, MD, PhD5*, Marie-Sarah Dilhuydy, MD6*, Romain Guieze, MD7*, Pierre Feugier8*, Damien Roos-Weil, MD9*, Lise Willems, MD10*, Anne-Sophie Michallet, MD, PhD11*, Alain Jacques Delmer, MD12, Pietro Taverna, PhD13, Judith A. Fox, PhD14, Vincent Levy, MD, PhD15*, Florence Cymbalista, MD16 and Fanny Baran-Marszak, MD, PhD4*

1CHU Reims, Hôpital Robert Debré, Reims, France
2Hematology department, CHU Strasbourg, Strasbourg, France
3Laboratoire d'Hématologie, APHP Hôpital Avicenne, Bobigny, FRA
4Laboratoire d'hématologie, Hôpital Avicenne, Bobigny, France
5Hematology Department, IUCT-Oncopole, Toulouse, France
6CHU Hopitaux de Bordeaux, Pessac, France
7Clinical Hematology, University Hospital of Clermont-Ferrand, Unit of adult cell therapy and clinical hematology, Clermont Ferrand, France
8Hematology Department, CHU Nancy, Vandoeuvre Les Nancy Cedex, France
9Hematology Department,Sorbonne Universités, UPMC Univ Paris 06, GRC-11, Hopital Pitié-Salpêtrière, Paris, France
10Cochin Hospital, Hematology Department, Paris, France
11Service d'hématologie, Centre Léon Bérard, Lyon, France
12Hopital Robert Debre CHU de Reims, Reims, Cedex, France
13Sunesis Pharmaceuticals, South San Francisco, CA
14Sunesis Pharmaceuticals, San Francisco, CA
15Hôpital Avicenne, Bobigny, France
16Laboratoire d'hématologie, Hôpital Avicenne, Bobigny Cedex, France

7:30 AM

Valeria Spina, PhD1, Gabriela Forestieri1*, Antonella Zucchetto2*, Alessio Bruscaggin, PhD1, Tamara Bittolo, PhD2*, Lodovico Terzi di Bergamo1*, Eva Szenes3*, Adalgisa Condoluci, MD1,4*, Erika Tissino, PhD2*, Lorenzo De Paoli, MD5*, Clara Deambrogi, PhD5*, Anna Maria Frustaci6*, Francesco Autore, MD7*, Michele Merli8*, Lydia Scarfo, MD9*, Claudia Cirillo Sanchez1*, Francesca Guidetti1*, Simone Favini5*, Fary Diop5*, Renzo Lucchini4*, Tanja N. Hartmann, Ph.D.3*, Giovanni Del Poeta, MD10, Roberto Marasca, MD11, Francesco Zaja12*, Bernhard Gerber4*, Emanuele Zucca, MD4, Georg Stussi, MD4, Jakob R. Passweg, MD, MS13, Paolo Ghia, MD, PhD14, Francesco Passamonti, MD15*, Michael Gregor, MD16*, Luca Laurenti, MD17*, Marco Montillo, MD6, Alessandra Tedeschi, MD6*, Franco Cavalli, MD4, Gianluca Gaidano, MD, PhD5, Valter Gattei, MD18 and Davide Rossi, MD, PhD1,4

1Institute of Oncology Research, Bellinzona, Switzerland
2Clinical and Experimental Onco-Hematology Unit, IRCCS Centro Di Riferimento Oncologico, Aviano, Italy
3Salzburg Cancer Research Institute, Salzburg, Salzburg, Austria
4Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
5Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
6Department of Haematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
7Hematology Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
8Department of Hematology,University of Insubria, Varese, Italy
9Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele, Milano, Italy
10Hematology, Ospedale S. Eugenio Universita 'Tor Vergata', Rome, Italy
11Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy
12Clinica Ematologica, DAME, University of Udine, Udine, Italy
13Hematology, University Hospital Basel, Basel, Switzerland
14Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele, Milan, Italy
15University Hospital Ospedale Di Circolo E Fondazione Macchi, VARESE, Italy
16Division of Hematology, Cantonal Hospital of Lucerne, Lucerne, Switzerland
17Istituto di Ematologia, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy
18Clinical and Experimental Onco-Hematology Unit, Centro Di Riferimento Oncologico, Aviano, Italy

7:45 AM

Sutapa Sinha, PhD1, Tammy Price-Troska, BS1*, Shulan Tian, MS, PhD2*, Charla R Secreto1*, Xiaosheng Wu, MD1*, Timothy G. Call, MD1, Rong He, MD3, Sameer A. Parikh, MD1, Saad S. Kenderian, MD1, Jose F. Leis, MD, PhD4, Huihuang Yan, PhD2*, Karen L Rech, MD3*, Minetta C Liu, MD5*, Stephen M. Ansell, MD, PhD1, Neil E. Kay, MD1 and Wei Ding, MD, PhD6

1Division of Hematology, Mayo Clinic, Rochester, MN
2Department of Health Science Research, Mayo Clinic, Rochester, MN
3Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
4Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ
5Department of Medical Oncology, Mayo Clinic, Rochester
6Mayo Clinic, Rochester, MN

8:00 AM

Ishwarya Murali, PhD, BS1,2, Siddha Kasar, PhD1,2*, Emily M. McWilliams, PhD1*, Gilad Itchaki1*, Svitlana Tyekucheva, PhD3*, Dimitri Livitz, BS2*, Ignaty Leshchiner, PhD2*, Shuai Dong, PhD4*, Stacey M. Fernandes, BS5*, Gad Getz, PhD2,6,7*, Amy J. Johnson, PhD4 and Jennifer R. Brown, MD, PhD1,2,8

1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
2Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA
3Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, MA
4Division of Hematology, Department of Internal Medicine and Comprehensive Cancer Center, The Ohio State University, Columbus, OH
5Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
6Department of Pathology, Harvard Medical School, Boston, MA
7Department of Pathology, Massachusetts General Hospital, Boston, MA
8Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

8:15 AM

Jennifer Edelmann, MD1, David James Britton, BSc, PhD2*, Emma Vilventhraraja, MSc, PhD2*, Arran Dokal, MSc, PhD2*, Karlheinz Holzmann, Dr. rer. nat.3*, Mark S Cragg, Prof4*, Andrejs Braun, PhD2*, Pedro Cutillas, PhD2* and John G. Gribben, Prof2

1Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, ENG, United Kingdom
2Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
3Center for Biomedical Research, Core Facility Genomics, Ulm University, Ulm, Germany
4Centre for Cancer Immunology, University of Southampton, Tenovus Research Laboratory, Southampton, United Kingdom

*signifies non-member of ASH